VULM 1457

• Description :

  VULM 1457 is a potent inhibitor of cholesterol acyltransferase (acyl-CoA) . VULM1457 significantly reduces production and secretion of adrenomedullin (AM) and down-regulates AM receptors on human hepatoblastic cells. VULM 1457 has remarkable hypolipidaemic activity and improves the overall myocardial ischaemia-reperfusion injury outcomes. VULM 1457 has the potential for the research of diabetes mellitus and hypercholesterolaemia[1][2].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319

• Target :

  Acyltransferase

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Metabolism-sugar/lipid metabolism

• Field of Research :

  Metabolic Disease; Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/vulm-1457.html

• Purity :

  99.71

• Solubility :

  DMSO : 125 mg/mL (ultrasonic)

• Smiles :

  O=C(NC1=CC=C(SC2=CC=C([N+]([O-])=O)C=C2)C=C1)NC3=C(C=CC=C3C(C)C)C(C)C

• Molecular Formula :

  C25H27N3O3S

• Molecular Weight :

  449.57

• Precautions :

  H302, H315, H319

• References & Citations :

  [1]Adameová A, et al. The myocardial infarct size-limiting and antiarrhythmic effects of acyl-CoA:cholesterol acyltransferase inhibitor VULM 1457 protect the hearts of diabetic-hypercholesterolaemic rats against ischaemia/reperfusion injury both in vitro and in vivo. Eur J Pharmacol. 2007;576 (1-3) :114-121.|[2]J Drímal, et al. The ACAT inhibitor VULM1457 significantly reduced production and secretion of adrenomedullin (AM) and down-regulated AM receptors on human hepatoblastic cells. Gen Physiol Biophys. 2005 Dec;24 (4) :397-409.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  ACAT

• CAS Number :

  [228544-65-8]